Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy.
Front Immunol
; 13: 922212, 2022.
Article
in En
| MEDLINE
| ID: mdl-36105799
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Follicular
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
Receptors, Chimeric Antigen
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Front Immunol
Year:
2022
Document type:
Article
Affiliation country:
China
Country of publication:
Switzerland